The company said it will use the funds to further validate its vertebral body augmentation system, VCFix, through testing and clinical studies. The system earned a breakthrough device designation from the FDA in September.
VCFix is a 3D-printed vertebral fracture implant that stimulates bone ingrowth and stability without bone cement.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.